Vesprini, D. (2013) “The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers”, Canadian Urological Association Journal, 5(2), pp. E31-E35. doi: 10.5489/cuaj.619.